



## Review

# Physiopathological rationale of using high-flow nasal therapy in the acute and chronic setting: A narrative review



Giulia Spoletini <sup>a, b</sup>, Andrea Cortegiani <sup>c, \*</sup>, Cesare Gregoretti <sup>c</sup>

<sup>a</sup> Respiratory Department, Gledhow Wing, St James's University Hospital, Leeds Teaching Hospital NHS Trust, Beckett Street, LS9 7TF, Leeds, UK

<sup>b</sup> Leeds Institute for Medical Research, Clinical Science Building, St James's University Hospital Campus, University of Leeds, Leeds, UK

<sup>c</sup> Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.). Section of Anesthesia, Analgesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, University of Palermo, Via del vespro 129, 90127, Palermo, Italy

## ARTICLE INFO

## Article history:

Received 12 January 2019

Received in revised form

18 February 2019

Accepted 20 February 2019

## Keywords:

Acute respiratory failure

High flow nasal therapy

Noninvasive ventilation

High flow nasal cannula

Chronic obstructive pulmonary disease

## ABSTRACT

Chronic lung disease and admissions due to acute respiratory failure (ARF) are becoming increasingly common. Consequently, there is a growing focus on optimizing respiratory support, particularly non-invasive respiratory support, to manage these conditions. High flow nasal therapy (HFNT) is a noninvasive technique where humidified and heated gas is delivered through the nose to the airways via small dedicated nasal prongs at flows that are higher than the rates usually applied during conventional oxygen therapy. HFNT enables to deliver different inspired oxygen fractions ranging from 0.21 to 1. Despite having only recently become available, the use of HFNT in the adult population is quite widespread in several clinical settings. The respiratory effects of HFNT in patients with respiratory failure may be particularly relevant for clinicians. In this narrative review, we discuss the main pathophysiological mechanism and rationale for using HFNT in the acute and chronic setting.

© 2019 Elsevier Ltd. All rights reserved.

## Contents

1. Introduction .....	23
2. Physiological mechanisms in acute respiratory failure .....	23
2.1. Effects of HFNT on muco-ciliary clearance .....	23
2.2. Effects on respiratory mechanics and oxygenation .....	24
2.2.1. Positive airway pressure .....	24
2.2.2. Increased inspiratory oxygen fraction and dead space wash out .....	24
2.2.3. Airway resistance .....	24
2.2.4. Humidification .....	24
2.3. Effects on respiratory pattern .....	25
2.4. Effects on comfort .....	25
2.4.1. Heating and humidification .....	25
2.4.2. Interface .....	25
3. Physiological mechanisms in long term chronic setting .....	25
3.1. Effects of HFNT on muco-ciliary clearance .....	25
3.2. Effects on respiratory mechanics .....	25

**Abbreviations:** Acute respiratory failure, ARF; High flow nasal therapy, HFNT; Conventional oxygen therapy, COT; Long-term oxygen therapy, LTOT; Acute hypercapnic respiratory failure, AHRF; Chronic obstructive pulmonary disease, COPD; Noninvasive ventilation, NIV; Positive airways pressure, PAP; Tidal volume, TV; Respiratory rate, RR.

\* Corresponding author.

E-mail addresses: [giulia.spoletini@nhs.net](mailto:giulia.spoletini@nhs.net) (G. Spoletini), [andrea.cortegiani@unipa.it](mailto:andrea.cortegiani@unipa.it) (A. Cortegiani), [c.gregoretti@gmail.com](mailto:c.gregoretti@gmail.com) (C. Gregoretti).

3.2.1. Positive airway pressure .....	25
3.2.2. Dead space wash out .....	26
3.2.3. Airway resistance .....	26
3.3. Effects on gas exchange .....	26
3.4. Effects on comfort .....	26
4. Summary and conclusion .....	26
Conflict of interest .....	26
Funding source .....	27
Acknowledgement .....	27
References .....	27

## 1. Introduction

The incidence of acute respiratory failure (ARF) among hospitalized patients and the prevalence of chronic lung conditions in the general population have been increasing steadily in the last decades [1,2]. As result, in recent years there has been a growing interest in optimizing techniques to provide adequate respiratory support, particularly by using non-invasive means.

Conventional oxygen therapy (COT) includes systems to deliver oxygen such as standard nasal cannulae, face masks, and Venturi masks. Traditionally, COT has been the first-line treatment in patients with hypoxemia in both the acute and chronic settings [3–5]. In patients with mild acute hypoxemia, COT can to improve oxygenation and outcomes [102]. Similarly, long-term oxygen therapy (LTOT) is the only treatment proven to reduce mortality in patients with chronic obstructive pulmonary disease (COPD) and chronic respiratory failure [6,7].

Non-invasive ventilation (NIV) is a ventilation delivery mode used routinely in the treatment of acute hypercapnic respiratory failure (AHRF) secondary to exacerbation of COPD [8], in ARF in immunocompromised patients [9] and ARF secondary to cardiogenic pulmonary edema [10]. NIV has been shown to reduce intubation rate and improve outcomes [10]. Conversely, its role in *de novo* hypoxemic ARF is still controversial, with conflicting results on its efficacy and poorer outcomes in this group of patients [11–13]. In the chronic setting, there is good evidence to support the long-term domiciliary use of NIV in both neuromuscular and extra-pulmonary restrictive disease [14,15]. More recently, a growing body of evidence has become available to support the already widespread use of long term NIV in patients with COPD and chronic ventilatory failure [14,16]. In these patients, NIV has been shown to improve gas exchange, quality of life, and reduce exacerbation and readmission rate [17–21].

Both COT and NIV suffer from known limitations. In particular, COT is unable to deliver accurate  $FIO_2$ , while NIV is associated with poor tolerability, patient-ventilator asynchrony due mainly to air leaks, and skin damage [8]. It is not unexpected, therefore, that new devices which could overcome some of these drawbacks are gaining increasing attention as an alternative form of respiratory support.

Among these is high flow nasal therapy (HFNT). This was initially developed for and extensively studied in the pediatric population [22], and recently has also been shown to be advantageous in adults, initially in the acute setting and more recently for long-term domiciliary use [23,24]. HFNT devices generate and deliver high flows (up to 60 L/min) of oxygen-enriched gas, at varying  $FIO_2$  between 21% and 100%, through large non-occlusive nasal prongs. The delivered gas mixture is actively heated to core temperature and humidified to full saturation, via a heated humidifier connected to the interface through a single-limb non-condensing insulated circuit. Despite having only recently become

available, the use of HFNT in the adult population is becoming more widespread. Several studies have shown the possible application of HFNT in *de novo* hypoxemic ARF [13,25–30], in immunocompromised patients [31], in the treatment and prevention of post-extubation respiratory failure [32,33], and in peri-operative medicine [34–38].

In these diverse clinical scenarios, HFNT has been studied in comparison to COT [25,33] or NIV [13], and more recently as a complementary therapy to NIV [39]. A small number of studies has focused on the role of HFNT in patients with stable COPD, showing a reduction in exacerbation rate and improvement in gas exchange [40–42].

Despite the need for further trials to confirm these results, the data available so far on HFNT, in both the acute and chronic settings, paint a very promising picture, and its use is anchored on a strong physiological rationale. In this narrative review, we discuss the main pathophysiological mechanisms and the rationale for the use of HFNT in both the acute and chronic setting.

## 2. Physiological mechanisms in acute respiratory failure

By delivering a gas mixture heated to body temperature and fully humidified at high flow rates, HFNT is beneficial to patients with acute respiratory failure, irrespective of the underlying cause. This is owing to its effects on muco-ciliary clearance, respiratory mechanics and work of breathing, and comfort (Table 1).

### 2.1. Effects of HFNT on muco-ciliary clearance

Muco-ciliary clearance is the first-line defense mechanism of the bronchial tree and depends on synchronous cilia movement and adequate water content in the mucus [43,44]. In physiological conditions, the upper airways are responsible for heating and humidifying the inspired air, in part by extracting humidity from the expired gas [45]. This process ensures that in the main bronchi and peripheral parts of the bronchial system the inspired air reaches a temperature of 37 C, an absolute humidity of 44 mg/L and a relative humidity of 100%. These are optimal conditions for the functioning of cilia, and to maintain mucus hydration [45,46]. Deviating from these conditions both with under- or over-humidification has been shown to negatively affect lung muco-ciliary clearance [46,47].

In ARF the elevated respiratory rate (RR) and patients' mouth breathing can affect proper airway humidification. This can cause mucus dehydration, impaired muco-ciliary clearance and eventually mucus retention [48]. In addition, medical gases, normally delivered through various forms of conventional respiratory support, contain only 6 parts per million of water vapour, contributing to airways dehydration [46]. Furthermore, the delivery of high flows of gases in tachypneic mouth-breathing patients under COT or NIV causes unidirectional nasal flows which lead the nasal mucosa to recover less moisture during expiration [49]. Therefore,

**Table 1**  
Potential mechanisms of benefit of HFNT in the acute setting.

Heating	Effects on muco-ciliary clearance Reduced metabolic cost of work of breathing Increased comfort
<b>Humidification</b>	Effects muco-ciliary clearance Reduced metabolic cost of work of breathing Reduced inflammation <i>in vitro</i> Increased comfort
<b>High-flow</b>	Positive airway pressure <ul style="list-style-type: none"> <li>• Recruitment effect</li> <li>• Increase dynamic lung compliance</li> <li>• Reduced work of breathing</li> </ul> Matching patients' PIFR <ul style="list-style-type: none"> <li>• Reliable delivery of FIO<sub>2</sub></li> <li>• Reduced inspiratory resistance</li> <li>• Reduced resistive component of WOB</li> </ul> Dead-space wash-out <ul style="list-style-type: none"> <li>• Reliable delivery of FIO<sub>2</sub></li> <li>• Reduced re-breathing</li> </ul>
<b>Interface</b>	Minimal instrumental dead-space Increased comfort

even if not bypassed, the upper airways cannot exert their heating and moisturizing effect and the lower airways mucosa become involved in the heating and humidification process, leading to increased mucosal inflammation, mucus dehydration with subsequent impaired cilia function and bronchial hyper-reactivity [46].

While cold air humidification with COT cannot significantly prevent these adverse events, the use of humidification during NIV treatment either via in-line heater humidifier or heat and moisture exchanger can [50]. Unfortunately, the absolute humidity that these systems deliver ranges between 5 and 30 mg/L, below the optimal conditions outlined above [51]. Conversely, HFNT provides the same level of absolute humidity found in the alveoli (44 mg/L) and it has been shown *in vitro* to be associated with lower level of inflammation and injury compared to conditions of under-humidification [46]. It is conceivable that this leads to restoration of the rheological properties of mucus, reducing the retention of secretions and the occurrence of atelectasis.

## 2.2. Effects on respiratory mechanics and oxygenation

Patients with acute respiratory failure present with increased work of breathing secondary to augmented inspiratory effort, respiratory rate (RR) and increased respiratory impedance. HFNT has been shown to reduce inspiratory effort compared to COT in patients with ARF, which translates clinically in improved outcomes on HFNT compared to both COT and NIV. These benefits can be explained by four key characteristics of HFNT: positive airway pressure, wash out of dead space, reduction in airway resistance and heating and humidification of the delivered gas.

### 2.2.1. Positive airway pressure

In the pediatric population, HFNT is known to be associated to reduced respiratory effort due to the positive pressure generated in the upper airways [22]. Similarly, in adults, HFNT generates a variable level of positive airways pressure (PAP) throughout the respiratory cycle. The PAP generated by HFNT depends on flow-rate and is higher at the end of expiration. During expiration, the PAP also depends on the volume of air leaked through the mouth, being higher when patients breathe with their mouth closed. During inspiration, the PAP does not however depend on the level of mouth closure [52–60]. It has been estimated that mean expiratory PAP can increase by 0.69 cmH<sub>2</sub>O for every 10 L/min of flow rate [56].

The PAP generated by HFNT can be approximated to a low-level

PEEP, being higher during expiration. This has been suggested to be the mechanism by which HFNT exerts a recruitment effect as shown by the increase in end-expiratory lung volume (EELV) in patients with acute and post-surgical respiratory failure [36,61,62]. In ARF, HFNT has not been associated with a significant increase in tidal volume (TV) [61,63], unlike to what observed in stable patients. Therefore, HFNT could reduce the risk of ventilation-induced lung injury possibly by reducing transpulmonary pressure. This is in contrast to NIV which is often associated with high tidal volume in *de novo* hypoxemic ARF [61,64].

HFNT has also been shown to reduce patients' inspiratory effort as observed clinically through a reduction in respiratory distress and use of accessory muscles [25–28]. Physiological studies [61,63,65] have shown, on HFNT compared to COT, a reduction of approximately 25% in the esophageal pressure swing, a measure of the inspiratory effort, and a decreased metabolic work of breathing as measured by trans-diaphragmatic pressure (P<sub>di</sub>) time product (PTP<sub>di</sub>). PTP<sub>di</sub> is the area under the P<sub>di</sub> signal from the onset of its positive deflection to its return to baseline [66]. These effects on respiratory mechanics, reported by one study to be most significant for flows of 60 L/min, do not show a clear dose-response with flow rates [61,63,65]. Current data seems to suggest that a tailored approach for each patient, consisting in bedside titration of the flows, could lead to optimal outcomes [62].

### 2.2.2. Increased inspiratory oxygen fraction and dead space wash out

HFNT delivers flow rates which match or are closer to patient peak inspiratory flow rate, usually between 30 and 120 L/min in ARF. Conversely, COT cannot meet the peak inspiratory flow rate, leading to the set FIO<sub>2</sub> not being delivered due to dilution with entrainment of room air in the gas mixture. HFNT not only reduces this effect [52,67,68], but by delivering high flow rates, washes out the upper airways dead space. This increases the FIO<sub>2</sub> and reduces the FICO<sub>2</sub>, minimizing the risk of re-breathing [69,70]. As a result, the FIO<sub>2</sub> delivered by HFNT is closer to the desired one, with mild discrepancies for flows lower than 40 L/min or in case of high peak inspiratory flow rates [71]. As an effect of this, alveolar pO<sub>2</sub> is increased, and oxygenation is improved. Similarly, CO<sub>2</sub> is cleared more efficiently on HFNT than on COT with reduced work of breathing to ensure adequate ventilation.

Finally, it is conceivable that dead-space wash-out can improve work of breathing in patients on HFNT as increasing dead-space, such as the instrumental one related to HME, has been associated with worsening work of breathing in patients treated with NIV [72].

### 2.2.3. Airway resistance

Due to their distensibility, the upper airways, and especially the nasopharynx, create resistance to the air flow. This becomes particularly relevant in situations that lead to a contraction of the upper airways, such as with the increase of peak inspiratory flow rate in ARF. Noninvasive continuous positive pressure ventilation (CPAP) and intermittent positive pressure ventilation (NIPPV), through a splinting effect and by delivering an inspiratory pressure respectively, can overcome this resistance. HFNT reduces inspiratory resistance and the resistive component of the work of breathing by matching the peak inspiratory flow rate and possibly by triggering the activation of the alae nasae muscle, thereby stiffening the airway [73–75].

### 2.2.4. Humidification

The energy expenditure for the human body to heat and humidify the inspired gas in physiological conditions (TV 500 ml and RR 12/min) has been estimated to be 156 calories/min [75]. This increases significantly when patients are in ARF, tachypneic and

breathing with their mouth open. HFNT provides a pre-conditioned gas mixture, reducing therefore the metabolic component of work of breathing.

### 2.3. Effects on respiratory pattern

As a consequence of the mechanisms described above, HFNT can affect the respiratory pattern in patients in various clinical scenarios, including healthy people [74]. HFNT in ARF tends to reduce respiratory rate, relieving patients' distress, and to increase tidal volume with reduction in dead space [61].

### 2.4. Effects on comfort

#### 2.4.1. Heating and humidification

Patients treated with low-flow oxygen report minimal or no discomfort on treatment, hence clinical guidelines do not recommend the routine use of humidification in such circumstances [3,76]. However, critically ill patients in ARF, who are often treated with higher flows of oxygen via face mask, are known to report discomfort on oxygen therapy, including airway dryness, despite the use of humidification [77]. Similarly, critically ill patients on NIV often report mucosal dryness in the nose, mouth and throat and this limits their comfort, leading to a higher risk of treatment failure [78,79]. The use of humidification appears to reduce the perceived dryness on NIV, although in a fashion not necessarily correlated with the level of delivered absolute humidity [48,80].

HFNT has been consistently shown to provide greater overall comfort to patients compared to both COT and NIV, including to patients with *de novo* ARF or post-extubation respiratory failure. This has mostly been attributed to the delivery of warmed and humidified gas through an in-line heated humidifier, which reduces airway dryness. However, only a handful of studies directly assessed subjective or objective measures of airway dryness using numeric rating scales or specialist assessment by otorhinolaryngologists. While most studies show a noticeable reduction in the perceived or measured dryness in the nose, mouth and throat, results are not consistent across the studies. Studies comparing HFNT to NIV or COT with added in-line humidification show that a similar fraction of patients reported airway dryness [39]. This would suggest that the greater overall comfort consistently observed on HFNT is associated with factors other than humidification, such as comfort of the interface.

#### 2.4.2. Interface

Critically ill patients usually receive COT via face masks or NIV via oronasal masks, full-face masks, or helmets, depending on patients' characteristics and needs [81,82]. The interface plays a central role in the improvement of comfort of HFNT compared to NIV.

The interfaces used for NIV in ARF suffer from several problems. One of them is the high instrumental dead space introduced by masks or helmets in NIV, which is almost negligible for nasal prongs used in HFNT. NIV interfaces suffer also from air leaks, which – in an attempt to be compensated by the clinician – cause the development of pressure sores, skin damage, and overall lead to poor tolerance. This, in turn, leads to the need for rotational strategies to be applied [50,82,83]. The nasal cannulae used on HFNT confer significant advantages to both COT and NIV. Not only the loose-fitting nasal prongs are reported to be more comfortable than those used for COT, but they are also associated with less displacement episodes, diminished eye irritation and greater ease eating [32,39].

Finally, it is conceivable that improving patient's comfort by optimizing airway humidification and interfaces may in turn lead

to reduced need for sedation thus decreasing the risk for delirium [84,85].

### 3. Physiological mechanisms in long term chronic setting

Over the last few years, a small number of case reports and studies have started looking at the potential role of HFNT in patients with sleep-disordered breathing, COPD and bronchiectasis. While the clinical evidence for the use of HFNT in the chronic setting is still very limited, more convincing data are available on its physiological rationale. The main effects by which HFNT could confer any advantages over COT or NIV in long-term domiciliary use are the same as in the acute setting, including its role on mucociliary clearance, improvement of respiratory mechanics and gas exchange and comfort (Table 2).

#### 3.1. Effects of HFNT on muco-ciliary clearance

Impaired muco-ciliary clearance in chronic respiratory conditions can be caused by various mechanisms, including decreased water content (i.e. Cystic Fibrosis), increased airways inflammation (i.e. COPD) or structural cilia damage (i.e. primary ciliary dyskinesia), and feeds into a vicious cycle leading to recurrent infections [43,44].

The central role of temperature and humidification in optimizing cilia function and mucus hydration [46], discussed previously, has been validated *in vivo* by showing that patients with bronchiectasis in treatment with HFNT (20–25 L/min, FIO<sub>2</sub> 21% 3 h/day for 6 days) had improved, but not normalized, lung clearance with no significant changes in cough frequency [86]. This improvement in the clearance index could explain how HFNT can reduce the rate of exacerbations in patients with bronchiectasis and COPD [42,87].

#### 3.2. Effects on respiratory mechanics

In COPD, structural changes and airflow obstruction with subsequent increased respiratory resistance lead to dynamic hyperinflation. Elastic and resistive loads are responsible for the increased work of breathing, which tends to be particularly evident during exacerbations and exercise [88]. However, this can evolve to be apparent during rest as well, and patients develop chronic respiratory failure.

##### 3.2.1. Positive airway pressure

In stable COPD, NIV improves alveolar ventilation altering the breathing pattern, and offloads the respiratory effort providing inspiratory pressure and counterbalancing the intrinsic PEEP [89]. The low-level PEEP effect exerted by HFNT has been described in stable patients with COPD and interstitial lung disease [54]. HFNT, used at relatively low flow rates in patients with stable COPD, leads to a reduction in P<sub>di</sub> swing, PTP<sub>di</sub> and dynamic intrinsic PEEP compared to baseline, but in a lesser measure than NIV [90,91]. These effects have been observed during wakefulness and in non-REM sleep [92]. This, together with the observed increase in TV [74,92] and end-expiratory lung volume, suggest an increase in the residual functional capacity. Finally, the use of HFNT improves the I:E compared to COT, due to an increase in expiratory time. These effects have been observed for flow rates at 20 and 30 L/min with patients breathing with their mouth closed, but were more pronounced for higher flows.

Patients with COPD often adopt strategies as pursed-lips breathing to increase the expiratory resistances as this can increase the expiratory time, reduce the respiratory rate and dynamic hyperinflation [93]. However, pursed-lips breathing may lead to

**Table 2**  
Potential mechanisms of benefit of HFNT in the chronic setting.

Heating	Effects on muco-ciliary clearance Increased comfort Reduced bronchoconstriction secondary to muscarinic activation
<b>Humidification</b>	Effects muco-ciliary clearance Reduced inflammation <i>in vitro</i> Increased comfort
<b>High-flow</b>	Positive airway pressure <ul style="list-style-type: none"> <li>• Recruitment effect</li> <li>• Increased tidal volume</li> <li>• Reduced work of breathing</li> <li>• Increased expiratory resistance</li> </ul> Matching patients' PIFR <ul style="list-style-type: none"> <li>• Reduced inspiratory resistance</li> <li>• Reduced resistive component of WOB</li> </ul> Dead-space wash-out <ul style="list-style-type: none"> <li>• Reliable delivery of FIO<sub>2</sub></li> <li>• Reduced re-breathing</li> </ul>
<b>Interface</b>	Increased comfort

an increased effort that the patient is not able to maintain over time. HFNT, by resembling the breathing pattern of pursed-lips breathing [74], may be a therapeutic tool for patients with COPD slowing respiratory rate and improving breathing pattern. Finally, the adoption of a deep and slow breathing pattern may reduce atelectasis [74].

In stabilized patients with Cystic Fibrosis, no differences in work of breathing as measured by diaphragmatic activity were observed while patients were at baseline, on HFNT or on NIV. However, HFNT resulted in mild improvement in VT compared to NIV and reduced RR compared to COT [94].

### 3.2.2. Dead space wash out

Studies on animal models suggested that the improved ventilation on HFNT is a consequence of flow rather than pressure [95]. Higher flow rates, by washing out the dead space in the upper and lower airways, improve pCO<sub>2</sub> or tCCO<sub>2</sub> clearance, reduce rebreathing and work of breathing in a flow-dependent manner with better results for flows greater than 30 L/min.

Furthermore, recent *in vivo* studies have confirmed that the reduction in pCO<sub>2</sub> in patients with stable hypercapnia is flow-dependent, and this effect could be more relevant than that of the generated pressure. In a small physiological study, pCO<sub>2</sub> dropped more significantly with higher flow rather than in those conditions where highest mean PAP was achieved [96].

### 3.2.3. Airway resistance

HFNT can reduce inspiratory resistance, leading to a reduction in dyspnea and respiratory rate. As aforementioned the effect on respiratory resistance exerted by HFNT is mainly due by meeting or exceeding the patient's peak inspiratory flow rate by supplying gas at a high flow. In addition, HFNT can also reduce bronchoconstriction by reducing the muscarinic effect [97] resulting from nasal inhalation of cold air in patients undergoing oxygen therapy [98].

This could have significant clinical implications during exercise and in symptomatic patients [89,99]. Alongside attenuating the inspiratory resistance, HFNT can increase the expiratory resistance through pressure effects and via the provision of continuous flow.

### 3.3. Effects on gas exchange

COT and NIV are used in the treatment of chronic respiratory failure to improve several significant outcomes, including quality of life, exacerbation rate, hospital readmission and mortality, through normalization or improvement in the gas exchange.

In most chronic respiratory conditions, this requires correcting both hypoxemia and hypercapnia. However, the studies available so far are limited to stable COPD with mild-moderate hypercapnia. In this setting, HFNT was consistently shown to decrease pCO<sub>2</sub>, as a consequence of the mechanisms above described, in both sleep and wakefulness. It has been suggested that changes in pulmonary mechanics, breathing pattern, flow rate, and higher baseline pCO<sub>2</sub> can affect the response to HFNT, with an average fall in pCO<sub>2</sub> by 10% for baseline values greater than 50 mmHg [100]. Conversely, results on oxygenation mostly show no changes in oxygen saturation, although a non-clinically-significant reduction in oxygenation has been observed during sleep and in short term physiological studies [92]. This could be because HFNT provides a more reliable delivery of a FIO<sub>2</sub> than COT which could lead to a higher FIO<sub>2</sub> being provided to patients.

### 3.4. Effects on comfort

Contrary to studies and results on ARF, results on comfort and dyspnea are inconsistent in patients with chronic respiratory failure who could be potential candidate for the domiciliary use of HFNT.

Interestingly long-term studies have shown that HFNT is well tolerated, and reduces dyspnea compared to LTOT [41,42], but when used in the short-term HFNT does not provide similar results in patients with COPD or CF [90,91,94]. Despite the lack of side effects, patients have reported overall comfort to be better or similar on LTOT and NIV compared to HFNT [90,91,101]. On this treatment the highest level of tolerability appeared to be achieved when the delivered flow was 30 L/min [101].

## 4. Summary and conclusion

In conclusion, HFNT entails several physiopathological mechanisms which can lead to improve patient's clinical condition both in acute and in chronic setting. Although these mechanisms have been demonstrated to improve patients' outcomes in some clinical scenarios, other applications, particularly in the chronic setting, require important issues to be resolved, such as timing of treatment and escalation plan to more invasive tools. Further studies are warranted to investigate these important issues.

### Conflict of interest

Dr Spoletini and Dr Cortegiani declare no conflict of interest. Dr

Gregoretti received fees for consultancies or lectures from Orion Pharma, ResMed, Medtronic, Philips, Air Liquide and EOVE.

### Funding source

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### Acknowledgement

The authors would like to thank Laura Caley for assistance in language editing and proof-reading.

### References

- [1] M.S. Stefan, M.-S. Shieh, P.S. Pekow, M.B. Rothberg, J.S. Steingrub, T. Lagu, P.K. Lindenauer, M.S. Stefan, Epidemiology and outcomes of acute respiratory failure in the United States, 2001 to 2009: a national survey, *J. Hosp. Med.* 8 (2013) 76–82.
- [2] GBD 2015 Chronic Respiratory Disease Collaborators, Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015, *Lancet Respir Med* 5 (2017) 691–706.
- [3] T.J. Kallstrom, American Association for Respiratory Care (AARC), AARC Clinical Practice Guideline: oxygen therapy for adults in the acute care facility—2002 revision & update, *Respir. Care* 47 (2002), 717–20.
- [4] M. Hardinge, J. Annandale, S. Bourne, B. Cooper, A. Evans, D. Freeman, A. Green, S. Hippolyte, V. Knowles, W. MacNee, L. McDonnell, K. Pye, J. Suntharlingam, V. Vora, T. Wilkinson, British thoracic society guidelines for home oxygen use in adults, *Thorax* 70 (2015) i1–i43.
- [5] B.R. O'Driscoll, L.S. Howard, J. Earis, V. Mak, British Thoracic Society Emergency Oxygen Guideline Group, BTS Emergency Oxygen Guideline Development Group, BTS guideline for oxygen use in adults in healthcare and emergency settings, *Thorax* 72 (2017) iii1–iii90.
- [6] NOTT Study group, Is 12-hour oxygen as effective as 24-hour oxygen in advanced chronic obstructive pulmonary disease with hypoxemia? (The nocturnal oxygen therapy trial—NOTT), *Chest* 78 (1980) 419–420.
- [7] NOTT study group, Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal oxygen therapy trial group, *Ann. Intern. Med.* 93 (1980) 391–398.
- [8] C. Gregoretti, L. Pisani, A. Cortegiani, V.M. Ranieri, Noninvasive ventilation in critically ill patients, *Crit. Care Clin.* 31 (2015) 435–457.
- [9] Cortegiani A, Madotto F, Gregoretti C, Bellani G, Laffey JG, Pham T, Van Haren F, Giarratano A, Antonelli M, Pesenti A, Grasselli G, LUNG SAFE Investigators and the ESICM Trials Group (2018) Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database. *Crit. Care* 22:157
- [10] B. Rochweg, L. Brochard, M.W. Elliott, D. Hess, N.S. Hill, S. Nava, P. Navalesi, M. Antonelli, J. Brozek, G. Conti, M. Ferrer, K. Guntupalli, S. Jaber, S. Keenan, J. Mancebo, S. Metha, S. Raoof, Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure, *Eur. Respir. J.* 50 (2017) 1602426.
- [11] N.S. Hill, E. Garpestad, G. Schumaker, G. Spoletini, Noninvasive ventilation for acute hypoxemic respiratory failure/ARDS – is there a role? *Turkish J Anesth Reanim* 45 (2018) 332–334.
- [12] A. Cortegiani, V. Russotto, M. Antonelli, E. Azoulay, A. Carlucci, G. Conti, A. Demoule, M. Ferrer, N.S. Hill, S. Jaber, P. Navalesi, P. Pelosi, R. Scala, C. Gregoretti, Ten important articles on noninvasive ventilation in critically ill patients and insights for the future: a report of expert opinions, *BMC Anesthesiol.* 17 (2017) 122.
- [13] J.-P. Frat, A.W. Thille, A. Mercat, C. Girault, S. Ragot, S. Perbet, G. Prat, T. Boulain, E. Morawiec, A. Cottareau, J. Devaquet, S. Nseir, K. Razazi, J.P. Mira, L. Argaud, J.C. Chakarian, J.D. Ricard, X. Wittebole, S. Chevalier, A. Herbland, M. Fartoukh, J.M. Constantin, J.M. Tonnelier, M. Pierrot, A. Mathonnet, G. Beduneau, C. Deletage-Metreau, J.C. Richard, L. Brochard, F. Robert, FLORALI study group; REVA network, High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure, *N. Engl. J. Med.* 372 (2015) 2185–2196.
- [14] S.J. Lloyd-Owen, G.C. Donaldson, N. Ambrosino, J. Escarabill, R. Farre, B. Fauroux, D. Robert, B. Schoenhofer, A.K. Simonds, J.A. Wedzicha, Patterns of home mechanical ventilation use in Europe: results from the Eurovent survey, *Eur. Respir. J.* 25 (2005) 1025–1031.
- [15] D. Robert, L. Argaud, Clinical review: long-term noninvasive ventilation, *Crit. Care* 11 (2007) 210.
- [16] C. Crimi, A. Noto, P. Princi, A. Cuvelier, J.F. Masa, A. Simonds, M. Elliott, P. Wijkstra, W. Windisch, S. Nava, Domiciliary noninvasive ventilation (NIV) in severe COPD patients: a European survey about indications and practices, *ERS Journals* (2014).
- [17] M.W. Elliott, D.A. Mulvey, J. Moxham, M. Green, M.A. Branthwaite, Domiciliary nocturnal nasal intermittent positive pressure ventilation in COPD: mechanisms underlying changes in arterial blood gas tensions, *Eur. Respir. J.* 4 (1991) 1044–1052.
- [18] D.J. Meecham Jones, E.A. Paul, P.W. Jones, J.A. Wedzicha, Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD, *Am. J. Respir. Crit. Care Med.* 152 (1995) 538–544.
- [19] A. Nickol, N. Hart, N.S. Hopkinson, C.-H. Hamnegård, J. Moxham, A. Simonds, M.I. Polkey, Mechanisms of improvement of respiratory failure in patients with COPD treated with NIV, *Int. J. Chronic Obstr. Pulm. Dis.* 3 (2008) 453–462.
- [20] T. Köhnlein, W. Windisch, D. Köhler, A. Drabik, J. Geiseler, S. Hartl, O. Karg, G. Laier-Groeneveld, S. Nava, B. Schonhofer, K. Wegscheider, C.P. Criege, T. Welte, Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multi-centre, randomised, controlled clinical trial, *Lancet Respir Med* 2 (2014) 698–705.
- [21] P.B. Murphy, S. Rehal, G. Arbane, S. Bourke, P.M.A. Calverley, A.M. Crook, L. Dowson, N. Duffy, G.J. Gibson, P.D. Hughes, J.R. Hurst, R. Mukherjee, A. Nickol, N. Oscroft, M. Patout, J. Pepperell, I. Smith, J.R. Stradling, J.A. Wedzicha, M.I. Polkey, M.W. Elliott, N. Hart, Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation, *J. Am. Med. Assoc.* 317 (2017) 2177.
- [22] Schibler A, Franklin, Nasal high-flow therapy in infants and children, *Pediatr Respiriol Crit Care Med* 2 (2018) 2.
- [23] G. Spoletini, M. Alotaibi, F. Blasi, N.S. Hill, Heated humidified high-flow nasal oxygen in adults: mechanisms of action and clinical implications, *Chest* 138 (2015) 253–261.
- [24] L. Pisani, M.L. Vega, Use of nasal high flow in stable COPD: rationale and physiology, *COPD* 14 (2017) 346–350.
- [25] O. Roca, J. Riera, F. Torres, J.R. Masclans, High-flow oxygen therapy in acute respiratory failure, *Respir. Care* 55 (2010) 408–413.
- [26] B. Sztrymf, J. Messika, T. Mayot, H. Lenglet, D. Dreyfuss, J.-D. Ricard, Impact of high-flow nasal cannula oxygen therapy on intensive care unit patients with acute respiratory failure: a prospective observational study, *J. Crit. Care* 27 (2012), 324.e9–13.
- [27] B. Sztrymf, J. Messika, F. Bertrand, D. Hurel, R. Leon, D. Dreyfuss, J.-D. Ricard, Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study, *Intensive Care Med.* 37 (2011) 1780–1786.
- [28] H. Lenglet, B. Sztrymf, C. Leroy, P. Brun, D. Dreyfuss, J.-D. Ricard, Humidified high flow nasal oxygen during respiratory failure in the emergency department: feasibility and efficacy, *Respir. Care* 57 (2012) 1873–1878.
- [29] J. Messika, K. Ben Ahmed, S. Gaudry, R. Migueel-Montanes, C. Rafat, B. Sztrymf, D. Dreyfuss, J.-D. Ricard, Use of high-flow nasal cannula oxygen therapy in subjects with ARDS: a 1-year observational study, *Respir. Care* 60 (2015) 162–169.
- [30] Y. Helviz, S. Einav, A systematic review of the high-flow nasal cannula for adult patients, *Crit. Care* 22 (2018) 71.
- [31] A. Cortegiani, C. Crimi, F. Sanfilippo, A. Noto, D. Di Falco, G. Grasselli, C. Gregoretti, A. Giarratano, High flow nasal therapy in immunocompromised patients with acute respiratory failure: a systematic review and meta-analysis, *J. Crit. Care* 50 (2019) 250–256.
- [32] S.M. Maggiore, F.A. Idone, R. Vaschetto, R. Festa, A. Cataldo, F. Antonicelli, L. Montini, A. De Gaetano, P. Navalesi, M. Antonelli, Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome, *Am. J. Respir. Crit. Care Med.* 190 (2014) 282–288.
- [33] G. Hernández, C. Vaquero, P. González, C. Subira, F. Frutos-Vivar, G. Rialp, C. Laborda, L. Colinas, R. Cuenca, R. Fernández, Effect of postextubation high-flow nasal cannula vs conventional oxygen therapy on reintubation in low-risk patients, *J. Am. Med. Assoc.* 315 (2016) 1354–1361.
- [34] B.M. Ansari, M.P. Hogan, T.J. Collier, R.A. Baddeley, M. Scarci, A.S. Coonar, F.E. Bottrill, G.C. Martinez, A.A. Klein, A randomized controlled trial of high-flow nasal oxygen (optiflow) as part of an enhanced recovery program after lung resection surgery, *Ann. Thorac. Surg.* 101 (2015) 459–464.
- [35] F. Stéphan, B. Barrucand, P. Petit, et al., High-flow nasal oxygen vs noninvasive positive airway pressure in hypoxic patients after cardiothoracic surgery, *J. Am. Med. Assoc.* 313 (2015) 2331–2339.
- [36] A. Corley, T. Bull, A.J. Spooner, A.G. Barnett, J.F. Fraser, Direct extubation onto high-flow nasal cannulae post-cardiac surgery versus standard treatment in patients with a BMI  $\geq 30$ : a randomised controlled trial, *Intensive Care Med.* 41 (2015) 887–894.
- [37] A. Cortegiani, G. Accurso, S. Mercadante, A. Giarratano, C. Gregoretti, High flow nasal therapy in perioperative medicine: from operating room to general ward, *BMC Anesthesiol.* 18 (2018) 166.
- [38] V. Russotto, A. Cortegiani, S.M. Raineri, C. Gregoretti, A. Giarratano, Respiratory support techniques to avoid desaturation in critically ill patients requiring endotracheal intubation: a systematic review and meta-analysis, *J. Crit. Care* 41 (2017) 98–106.
- [39] G. Spoletini, C. Mega, L. Pisani, M. Alotaibi, A. Khoja, L.L. Price, F. Blasi, S. Nava, N.S. Hill, High-flow nasal therapy vs standard oxygen during breaks off noninvasive ventilation for acute respiratory failure: a pilot randomized controlled trial, *J. Crit. Care* 48 (2018) 418–425.
- [40] J. Bräunlich, M. Köhler, H. Wirtz, Nasal highflow improves ventilation in

- patients with COPD, *Int. J. Chronic Obstr. Pulm. Dis.* 11 (2016) 1077.
- [41] K. Nagata, T. Kikuchi, T. Horie, A. Shiraki, T. Kitajima, T. Kadowaki, F. Tokioka, Nm Chohnabayashi, A. Watanabe, S. Sato, K. Tomii, Domiciliary high-flow nasal cannula oxygen therapy for patients with stable hypercapnic chronic obstructive pulmonary disease. A multicenter randomized crossover trial, *Ann Am Thorac Soc* 15 (2018) 432–439.
- [42] L.H. Storgaard, H. Hockey, B.S. Laursen, U.M. Weinreich, Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure, *Int. J. Chronic Obstr. Pulm. Dis.* 13 (2018) 1195–1205.
- [43] A. Wanner, M. Salathé, T.G. O'Riordan, Mucociliary clearance in the airways, *Am. J. Respir. Crit. Care Med.* 154 (1996) 1868–1902.
- [44] E. Houtmeyers, R. Gosselink, G. Gayan-Ramirez, M. Decramer, Regulation of mucociliary clearance in health and disease, *Eur. Respir. J.* 13 (1999) 1177–1188.
- [45] A. Sahin-Yilmaz, R.M. Naclerio, Anatomy and physiology of the upper airway, *Proc. Am. Thorac. Soc.* 8 (2011) 31–39.
- [46] A. Chidekel, Y. Zhu, J. Wang, J.J. Mosko, E. Rodriguez, T.H. Shaffer, The effects of gas humidification with high-flow nasal cannula on cultured human airway epithelial cells, *Pulm Med* (2012), 2012:380686.
- [47] E. Kilgour, N. Rankin, S. Ryan, R. Pack, Mucociliary function deteriorates in the clinical range of inspired air temperature and humidity, *Intensive Care Med.* 30 (2004) 1491–1494.
- [48] F. Lellouche, E. L'Her, F. Abroug, et al., Impact of the humidification device on intubation rate during noninvasive ventilation with ICU ventilators: results of a multicenter randomized controlled trial, *Intensive Care Med.* 40 (2014) 211–219.
- [49] G.N. Richards, P.A. Cistulli, R.G. Ungar, M. Berthon-Jones, C.E. Sullivan, Mouth leak with nasal continuous positive airway pressure increases nasal airway resistance, *Am. J. Respir. Crit. Care Med.* 154 (1996) 182–186.
- [50] S. Nava, P. Navalesi, C. Gregoretti, Interfaces and humidification for noninvasive mechanical ventilation, *Respir. Care* 54 (2009) 71–84.
- [51] F. Lellouche, S.M. Maggione, A. Lyazidi, N. Deye, S. Taillé, L. Brochard, Water content of delivered gases during non-invasive ventilation in healthy subjects, *Intensive Care Med.* 35 (2009) 987–995.
- [52] M.A.B. Sim, P. Dean, J. Kinsella, R. Black, R. Carter, M. Hughes, Performance of oxygen delivery devices when the breathing pattern of respiratory failure is simulated, *Anaesthesia* 63 (2008) 938–940.
- [53] N. Groves, A. Tobin, High flow nasal oxygen generates positive airway pressure in adult volunteers, *Aust. Crit. Care* 20 (2007) 126–131.
- [54] J. Braunlich, D. Beyer, D. Mai, S. Hammerschmidt, H.J. Seyfarth, H. Wirtz, Effects of nasal high flow in ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients, *Respiration* 85 (2012) 319–325.
- [55] R. Parke, S. McGuinness, M. Eccleston, Nasal high-flow therapy delivers low level positive airway pressure, *Br. J. Anaesth.* 103 (2009) 886–890.
- [56] R.L. Parke, M.L. Eccleston, S.P. McGuinness, The effects of flow on airway pressure during nasal high-flow oxygen therapy, *Respir. Care* 56 (2011) 1151–1155.
- [57] R.L. Parke, S.P. McGuinness, Pressures delivered by nasal high flow oxygen during all phases of the respiratory cycle, *Respir. Care* 58 (2013) 1621–1624.
- [58] R. Parke, S. McGuinness, R. Dixon, A. Jull, Open-label, phase II study of routine high-flow nasal oxygen therapy in cardiac surgical patients, *Br. J. Anaesth.* 111 (2013) 925–931.
- [59] R.L. Parke, A. Bloch, S.P. McGuinness, Effect of very-high-flow nasal therapy on airway pressure and end-expiratory lung impedance in healthy volunteers, *Respir. Care* 60 (2015) 1397–1403.
- [60] A. Corley, L.R. Caruana, A.G. Barnett, O. Tronstad, J.F. Fraser, Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in post-cardiac surgical patients, *Br. J. Anaesth.* 107 (2011) 998–1004.
- [61] T. Mauri, C. Turrini, N. Eronia, G. Grasselli, C.A. Volta, G. Bellani, A. Pesenti, Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure, *Am. J. Respir. Crit. Care Med.* 195 (2017) 1207–1215.
- [62] T. Mauri, L. Alban, C. Turrini, B. Cambiaghi, E. Carlesso, P. Taccone, N. Bottino, A. Lissoni, S. Spadaro, C.A. Volta, L. Gattinoni, A. Pesenti, G. Grasselli, Optimum support by high-flow nasal cannula in acute hypoxemic respiratory failure: effects of increasing flow rates, *Intensive Care Med.* 43 (2017) 1453–1463.
- [63] M. Delorme, Pierre-alexandre Bouchard, S. Simon, M. Simard, F. Lellouche, Effects of high-flow nasal cannula on the work of breathing in patients recovering from acute respiratory failure\*, *Crit. Care Med.* 45 (2017) 1981–1988.
- [64] G. Carteaux, T. Millán-Guilarte, N. De Prost, K. Razazi, S. Abid, A.W. Thille, F. Schortgen, L. Brochard, C. Brun-Buisson, A. Mekontso Dessap, Failure of noninvasive ventilation for de novo acute hypoxemic respiratory failure, *Crit. Care Med.* 44 (2016) 282–290.
- [65] F. Vargas, M. Saint-Leger, A. Boyer, N.H. Bui, G. Hilbert, Physiologic effects of high-flow nasal cannula oxygen in critical care subjects, *Respir. Care* 60 (2015) 1369–1376.
- [66] E. Vivier, A. Mekontso Dessap, S. Dimassi, F. Vargas, A. Lyazidi, A.W. Thille, L. Brochard, Diaphragm ultrasonography to estimate the work of breathing during non-invasive ventilation, *Intensive Care Med.* 38 (2012) 796–803.
- [67] T.A.J. Wagstaff, N. Soni, Performance of six types of oxygen delivery devices at varying respiratory rates, *Anaesthesia* 62 (2007) 492–503.
- [68] J.E.E. Ritchie, A.B. Williams, C. Gerard, H. Hockey, Evaluation of humidified nasal high flow oxygen system, using oxygraphy, capnography and measurement of upper airway pressures, *Anaesth. Intensive Care* 39 (2011) 1103–1110.
- [69] W. Möller, G. Celik, S. Feng, P. Bartenstein, G. Meyer, E. Oliver, O. Schmid, S. Tatkov, Nasal high flow clears anatomical dead space in upper airway models, *J. Appl. Physiol.* 118 (2015) 1525–1532.
- [70] W. Möller, S. Feng, U. Domanski, K.J. Franke, G. Celik, P. Bartenstein, S. Becker, G. Meyer, O. Schmid, O. Eickelberg, S. Tatkov, G. Nilius, Nasal high flow reduces dead space, *J. Appl. Physiol.* 122 (2017) 191–197.
- [71] Y. Chikata, M. Onodera, J. Oto, M. Nishimura, FIO<sub>2</sub> in an adult model simulating high-flow nasal cannula therapy, *Respir. Care* 62 (2017) 193–198.
- [72] R.S. Campbell, K. Davis, J.A. Johannigman, R.D. Branson, The effects of passive humidifier dead space on respiratory variables in paralyzed and spontaneously breathing patients, *Respir. Care* 45 (2000) 306–312.
- [73] A.R. Gold, P.L. Smith, A.R. Schwartz, Effect of alae nasi activation on maximal nasal inspiratory airflow in humans, *J. Appl. Physiol.* 84 (1998) 2115–2122.
- [74] T. Mundel, S. Feng, S. Tatkov, H. Schneider, T. Mündel, S. Feng, S. Tatkov, H. Schneider, Mechanisms of nasal high flow on ventilation during wakefulness and sleep, *J. Appl. Physiol.* 114 (2013) 1058–1065.
- [75] K. Dysart, T.L. Miller, M.R. Wolfson, T.H. Shaffer, Research in high flow therapy: mechanisms of action, *Respir. Med.* 103 (2009) 1400–1405.
- [76] E.J. Campbell, M.D. Baker, P. Crites-Silver, Subjective effects of humidification of oxygen for delivery by nasal cannula: a prospective study, *Chest* 93 (1988) 289–293.
- [77] G. Chanques, J.-M. Constantin, M. Sauter, B. Jung, M. Sebbane, D. Verzilli, J.-Y. Lefrant, S. Jaber, Discomfort associated with underhumidified high-flow oxygen therapy in critically ill patients, *Intensive Care Med.* 35 (2009) 996–1003.
- [78] E. Ozyilmaz, A.O. Ugurlu, S. Nava, Timing of noninvasive ventilation failure: causes, risk factors, and potential remedies, *BMC Pulm. Med.* 14 (2014) 19.
- [79] A. Carlucci, J.C. Richard, M. Wysocki, E. Lepage, L. Brochard, SRLP Collaborative Group on Mechanical Ventilation, Noninvasive versus conventional mechanical ventilation, *Am. J. Respir. Crit. Care Med.* 163 (2001) 874–880.
- [80] J. Oto, E. Nakataki, N. Okuda, M. Onodera, H. Imanaka, M. Nishimura, Hygroscopic properties of inspired gas and oral dryness in patients with acute respiratory failure during noninvasive ventilation, *Respir. Care* 59 (2014) 39–45.
- [81] C. Crimi, A. Noto, P. Princi, A. Esquinas, S. Nava, A European survey of noninvasive ventilation practices, *Eur. Respir. J.* 36 (2010) 362–369.
- [82] F. Racca, L. Appendini, G. Berta, L. Barberis, F. Vittone, C. Gregoretti, G. Ferreyra, R. Urbino, V.M. Ranieri, Helmet ventilation for acute respiratory failure and nasal skin breakdown in neuromuscular disorders, *Anesth. Analg.* 109 (2009) 164–167.
- [83] C. Gregoretti, G. Foti, F. Beltrame, P. Giugaro, P. Biolino, L. Burbi, M. Turello, F. Agostini, M. Berardino, P. Musto, Pressure control ventilation and mini-tracheotomy in treating severe flail chest trauma, *Intensive Care Med.* 21 (1995) 1054–1056.
- [84] G. Mistraretti, E.S. Mantovani, M. Berardino, Delirium: clinical approach and prevention, *Best Pract. Res. Clin. Anaesthesiol.* 26 (2012) 311–326.
- [85] G. Bellelli, A. Morandi, E. Zanetti, M. Bozzini, E. Lucchi, M. Terrasi, M. Trabucchi, Recognition and management of delirium among doctors, nurses, physiotherapists, and psychologists: an Italian survey, *Int. Psychogeriatr.* 26 (2014) 2093–2102.
- [86] A. Hasani, T.H. Chapman, D. McCool, R.E. Smith, J.P. Dilworth, J.E. Agnew, Domiciliary humidification improves lung mucociliary clearance in patients with bronchiectasis, *Chronic Respir. Dis.* 5 (2008) 81–86.
- [87] H. Rea, S. McAuley, L. Jayaram, J. Garrett, H. Hockey, L. Storey, G. O'Donnell, L. Haru, M. Payton, K. O'Donnell, The clinical utility of long-term humidification therapy in chronic airway disease, *Respir. Med.* 104 (2010) 525–533.
- [88] P. Laveneziana, J.A. Guenette, K.A. Webb, D.E. O'Donnell, New physiological insights into dyspnea and exercise intolerance in chronic obstructive pulmonary disease patients, *Expert Rev. Respir. Med.* 6 (2012) 651–662.
- [89] W. Chatila, T. Nugent, G. Vance, J. Gaughan, G.J. Criner, The effects of high-flow vs low-flow oxygen on exercise in advanced obstructive airways disease, *Chest* 126 (2004) 1108–1115.
- [90] J.F. Fraser, A.J. Spooner, K.R. Dunster, C.M. Anstey, A. Corley, Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial, *Thorax* 71 (2016) 759–761.
- [91] L. Pisani, L. Fasano, N. Corcione, V. Comellini, M.A. Musti, M. Brandao, D. Bottono, E. Calderini, P. Navalesi, S. Nava, Change in pulmonary mechanics and the effect on breathing pattern of high flow oxygen therapy in stable hypercapnic COPD, *Thorax* 72 (2017) 373–375.
- [92] P.J.C. Biselli, J.P. Kirkness, L. Grote, K. Fricke, A.R. Schwartz, P. Smith, H. Schneider, Nasal high-flow therapy reduces work of breathing compared with oxygen during sleep in COPD and smoking controls: a prospective observational study, *J. Appl. Physiol.* 122 (2017) 82–88.
- [93] J. Spahija, M. de Marchie, A. Grassino, Effects of imposed pursed-lips breathing on respiratory mechanics and dyspnea at rest and during exercise in COPD, *Chest* 128 (2005) 640–650.
- [94] M.C. Sklar, M. Dres, N. Rittayamai, B. West, D.L. Grieco, I. Telias, D. Junhasavasdikul, M. Rauseo, T. Pham, F. Madotto, C. Campbell, E. Tullis, L. Brochard, High-flow nasal oxygen versus noninvasive ventilation in adult patients with cystic fibrosis: a randomized crossover physiological study, *Ann. Intensive Care* 8 (2018) 85.

- [95] M. Frizzola, T.L. Miller, M.E. Rodriguez, Y. Zhu, J. Rojas, A. Hesek, A. Stump, T.H. Shaffer, K. Dysart, High-flow nasal cannula: impact on oxygenation and ventilation in an acute lung injury model, *Pediatr. Pulmonol.* 46 (2011) 67–74.
- [96] J. Bräunlich, F. Mauersberger, H. Wirtz, Effectiveness of nasal highflow in hypercapnic COPD patients is flow and leakage dependent, *BMC Pulm. Med.* 18 (2018) 14.
- [97] L.S. On, P. Boonyongsunchai, S. Webb, L. Davies, P.M.A. Calverley, R.W. Costello, Function of pulmonary neuronal M<sub>2</sub> muscarinic receptors in stable chronic obstructive pulmonary disease, *Am. J. Respir. Crit. Care Med.* 163 (2001) 1320–1325.
- [98] P. Fontanari, H. Burnet, M.C. Zattara-Hartmann, Y. Jammes, Changes in airway resistance induced by nasal inhalation of cold dry, dry, or moist air in normal individuals, *J. Appl. Physiol.* 81 (1996) 1739–1743.
- [99] S. Cirio, M. Piran, M. Vitacca, G. Piaggi, P. Ceriana, M. Prazzoli, M. Paneroni, A. Carlucci, Effects of heated and humidified high flow gases during high-intensity constant-load exercise on severe COPD patients with ventilatory limitation, *Respir. Med.* 118 (2016) 128–132.
- [100] J. Bräunlich, H. Wirtz, NHF and hypercapnia: how brief can you look? *Respirology* 22 (2017) 1049–1050.
- [101] S. McKinstry, J. Pilcher, G. Bardsley, J. Berry, S. Van de Hei, I. Braithwaite, J. Fingleton, M. Weatherall, R. Beasley, Nasal high flow therapy and PtCO<sub>2</sub> in stable COPD: a randomized controlled cross-over trial, *Respirology* 23 (2018) 378–384.
- [102] B.R. O'Driscoll, L.S. Howard, J. Earis, V. Mak, BTS guideline for oxygen use in adults in healthcare and emergency settings, *Thorax* 72 (2017) ii1–ii90.